April 10, 2014

Resolutions of the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd.




Basel, Switzerland, April 9, 2014 -Basilea Pharmaceutica Ltd. (SIX: BSLN) reported that at today's Ordinary General Meeting of Shareholders for the financial year 2013, shareholders approved all agenda items proposed by the Board of Directors. At the meeting, 51.3 percent of Basilea's share capital was represented.

The shareholders approved the annual report, the financial statements and consolidated financial statements for the business year 2013, and released the members of the Board of Directors and the Management Committee. Shareholders also approved carrying forward the accumulated deficit and re-elected PricewaterhouseCoopers AG, Basel as Statutory Auditors for the audit of the stand-alone and the consolidated financial statements for the business year 2014.

In addition, the shareholders approved the Board of Directors' proposal to amend the Articles of Incorporation ("Articles") in order to implement the Ordinance Against Excessive Compensation in Listed Companies, as well as the Board's other proposals for amendment of the Articles.

All current members of Basilea's Board of Directors were re-elected: Dr. Martin Nicklasson, Domenico Scala, Hans-Beat Gürtler, Prof. Daniel Lew, Dr. Thomas M. Rinderknecht, Steven D. Skolsky and Dr. Thomas Werner. Dr. Nicklasson was elected as the Chairman of the Board of Directors. The shareholders also elected Dr. Nicklasson, Mr. Skolsky and Dr. Werner as members of the Compensation Committee. Dr. Caroline Cron was elected as Independent Voting Rights Representative. The terms of all these individuals last until the end of the 2015 Ordinary General Meeting of Shareholders.

Finally, the shareholders approved the creation of Authorized Share Capital to provide Basilea with the flexibility to quickly respond to strategic opportunities. The authorization is valid for a period of two years.

In his presentation to shareholders, Chief Executive Officer Ronald Scott highlighted: "2013 was a very successful year for Basilea. We achieved key milestones including the approval of our antibiotic ceftobiprole in Europe and presented positive Phase 3 topline results for the antifungal isavuconazole. We are anticipating further significant milestones in 2014 such as the planned filing of isavuconazole in Europe and the U.S. as well as the launch of ceftobiprole in first key European countries. Basilea will continue to move forward to deliver life-saving drugs to patients and bring the company to sustainable profitability."

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research and development operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd., the company focuses on innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and non-response to current treatment options.


This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Media Relations Investor Relations
Peer Nils Schröder, PhD
Head Public Relations &
Corporate Communications
+41 61 606 1102
Barbara Zink, PhD, MBA
Head Corporate Development

+41 61 606 1233

This press release can be downloaded from www.basilea.com.